Asco 2015 – SWOG S1310: Randomized phase II trial of single agent MEK
- This topic has 1 reply, 2 voices, and was last updated 9 years, 6 months ago by
.
Viewing 2 posts - 1 through 2 (of 2 total)
-
Posts
-
We just met with a doctor yesterday and this one came up. It is suspended right now, but he had said they were showing some promise with it. Hopefully they figure out the issues and reopen it.
SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
http://abstracts.asco.org/156/AbstView_156_150637.html
Viewing 2 posts - 1 through 2 (of 2 total)
- The forum ‘Chemotherapy & More’ is closed to new topics and replies.